8461 related articles for article (PubMed ID: 22563888)
21. Immune modulation and safety profile of adoptive immunotherapy using expanded autologous activated lymphocytes against advanced cancer.
Sun Z; Shi L; Zhang H; Shao Y; Wang Y; Lin Y; Li X; Bai C
Clin Immunol; 2011 Jan; 138(1):23-32. PubMed ID: 21041120
[TBL] [Abstract][Full Text] [Related]
22. Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma.
Schmidt-Wolf IG; Finke S; Trojaneck B; Denkena A; Lefterova P; Schwella N; Heuft HG; Prange G; Korte M; Takeya M; Dorbic T; Neubauer A; Wittig B; Huhn D
Br J Cancer; 1999 Nov; 81(6):1009-16. PubMed ID: 10576658
[TBL] [Abstract][Full Text] [Related]
23. Anti-tumor activity of ex vivo expanded cytokine-induced killer cells against human hepatocellular carcinoma.
Kim HM; Lim J; Yoon YD; Ahn JM; Kang JS; Lee K; Park SK; Jeong YJ; Kim JM; Han G; Yang KH; Kim YJ; Kim Y; Han SB
Int Immunopharmacol; 2007 Dec; 7(13):1793-801. PubMed ID: 17996690
[TBL] [Abstract][Full Text] [Related]
24. Dendritic cells infected by Ad-sh-SOCS1 enhance cytokine-induced killer (CIK) cell immunotherapeutic efficacy in cervical cancer models.
Zheng Y; Hu B; Xie S; Chen X; Hu Y; Chen W; Li S; Hu B
Cytotherapy; 2017 May; 19(5):617-628. PubMed ID: 28215653
[TBL] [Abstract][Full Text] [Related]
25. Cytokine-induced killer (CIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors.
Mesiano G; Todorovic M; Gammaitoni L; Leuci V; Giraudo Diego L; Carnevale-Schianca F; Fagioli F; Piacibello W; Aglietta M; Sangiolo D
Expert Opin Biol Ther; 2012 Jun; 12(6):673-84. PubMed ID: 22500889
[TBL] [Abstract][Full Text] [Related]
26. [Selection of storage time, temperature and anticoagulants of peripheral blood samples for culturing cytokine-induced killer cells].
Wang Y; Ma F; Fu F; Wei Z; Dong Z; Zhu L; Luo X
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2016 Mar; 32(3):382-6. PubMed ID: 26927561
[TBL] [Abstract][Full Text] [Related]
27. [Short-term curative efficacy of autologous cytokine induced killer cells combined with low-dose IL-2 regimen containing immune enhancement by thymic peptide in elderly patients with B-cell chronic lymphocytic leukemia].
Cai LL; Yang Y; Yang B; Zhu HL; Lu XC; Zhang WY; Yu RL; Chi XH; Wang Y; Dai HR; Han WD; Fan H; Li SX; Liu Y; Ran HH; Lin J; Tuo S; Tuo CW; Zhang F; Cao JP; Yao SQ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Jun; 20(3):564-70. PubMed ID: 22739156
[TBL] [Abstract][Full Text] [Related]
28. Biological Character of RetroNectin Activated Cytokine-Induced Killer Cells.
Han L; Shang YM; Song YP; Gao QL
J Immunol Res; 2016; 2016():5706814. PubMed ID: 27433478
[TBL] [Abstract][Full Text] [Related]
29. [Application of immune function test to evaluate effect of cytokine-induced autologous killer cell infusion for elderly patients with hematological malignancies].
Cai LL; Yang B; Lu XC; Zhu HL; Han WD; Wang Y; Liu Y; Dai HR; Yao SQ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Oct; 18(5):1250-5. PubMed ID: 21129270
[TBL] [Abstract][Full Text] [Related]
30. Cytotoxic potential of IL-15-activated cytokine-induced killer cells against human neuroblastoma cells.
Cappel C; Huenecke S; Suemmerer A; Erben S; Rettinger E; Pfirrmann V; Heinze A; Zimmermann O; Klingebiel T; Ullrich E; Bader P; Bremm M
Pediatr Blood Cancer; 2016 Dec; 63(12):2230-2239. PubMed ID: 27433920
[TBL] [Abstract][Full Text] [Related]
31. [Comparison of Several Optimization Schemes for the Induction and Expansion of Antibody-Mediated High Efficiency CIK (AMHE-CIK) In Vitro].
Yin X; Xu X; Zhao Y; Wang ZJ; Wang HY; Hu ZB
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Feb; 24(1):191-6. PubMed ID: 26913419
[TBL] [Abstract][Full Text] [Related]
32. Cytokine-induced killer cells against autologous CLL: direct cytotoxic effects and induction of immune accessory molecules by interferon-gamma.
Kornacker M; Moldenhauer G; Herbst M; Weilguni E; Tita-Nwa F; Harter C; Hensel M; Ho AD
Int J Cancer; 2006 Sep; 119(6):1377-82. PubMed ID: 16642465
[TBL] [Abstract][Full Text] [Related]
33. Increase in Efficacy of Checkpoint Inhibition by Cytokine-Induced-Killer Cells as a Combination Immunotherapy for Renal Cancer.
Dehno MN; Li Y; Weiher H; Schmidt-Wolf IGH
Int J Mol Sci; 2020 Apr; 21(9):. PubMed ID: 32349280
[TBL] [Abstract][Full Text] [Related]
34. Autologous cytokine-induced killer cell therapy in lung cancer patients: a retrospective study.
Zhang J; Zhu L; Du H; He X; Yin Y; Gu Y; Liu L; Lu K; Guo R; Liu P; Shu Y
Biomed Pharmacother; 2015 Mar; 70():248-52. PubMed ID: 25776508
[TBL] [Abstract][Full Text] [Related]
35. Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma.
Lee JH; Lee JH; Lim YS; Yeon JE; Song TJ; Yu SJ; Gwak GY; Kim KM; Kim YJ; Lee JW; Yoon JH
Gastroenterology; 2015 Jun; 148(7):1383-91.e6. PubMed ID: 25747273
[TBL] [Abstract][Full Text] [Related]
36. The dual-functional capability of cytokine-induced killer cells and application in tumor immunology.
Zhang Q; Liu XY; Zhang T; Zhang XF; Zhao L; Long F; Liu ZK; Wang EH
Hum Immunol; 2015 May; 76(5):385-91. PubMed ID: 25305457
[TBL] [Abstract][Full Text] [Related]
37. Restoration of CD3
Dai H; Zhou Y; Tong C; Guo Y; Shi F; Wang Y; Shen P
Cytotherapy; 2018 Sep; 20(9):1155-1163. PubMed ID: 30100374
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of cord blood-derived cytokine-induced killer cells in treatment of patients with malignancies.
Zhang Z; Wang L; Luo Z; Zhao X; Huang J; Li H; Yang S; Zhao X; Zhang L; Li L; Wang F; Huang L; Zhang Y
Cytotherapy; 2015 Aug; 17(8):1130-8. PubMed ID: 25963952
[TBL] [Abstract][Full Text] [Related]
39. Adoptive immunotherapy of human gastric cancer with ex vivo expanded T cells.
Kim YJ; Lim J; Kang JS; Kim HM; Lee HK; Ryu HS; Kim JY; Hong JT; Kim Y; Han SB
Arch Pharm Res; 2010 Nov; 33(11):1789-95. PubMed ID: 21116782
[TBL] [Abstract][Full Text] [Related]
40. Influence of the number and interval of treatment cycles on cytokine-induced killer cells and their adjuvant therapeutic effects in advanced non-small-cell lung cancer (NSCLC).
Gu Y; Lv H; Zhao J; Li Q; Mu G; Li J; Wuyang J; Lou G; Wang R; Zhang Y; Huang X
Int Immunopharmacol; 2017 Sep; 50():263-269. PubMed ID: 28711032
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
